GlucoTrack Inc (GCTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlucoTrack Inc (GCTK) has a cash flow conversion efficiency ratio of -1.392x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.94 Million) by net assets ($2.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GlucoTrack Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how GlucoTrack Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GlucoTrack Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
GlucoTrack Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlucoTrack Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PSYCHED WELLNESS LTD
F:5U9
|
-0.323x |
|
Monarca Minerals Inc
V:MMN
|
0.008x |
|
Middlefield Canadian Income PCC - Middlefield Canadian Income - GBP PC
LSE:MCT
|
0.005x |
|
Drugs Made In America Acquisition Corp. Rights
NASDAQ:DMAAR
|
N/A |
|
Labrador Technologies Inc
V:LTX
|
0.099x |
|
Alexium International Group Limited
F:E7T
|
-0.087x |
|
NTR Holding A/S
CO:NTR-B
|
-0.080x |
|
PREMIA FINANCE O.N.
F:81U
|
N/A |
Annual Cash Flow Conversion Efficiency for GlucoTrack Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of GlucoTrack Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see GlucoTrack Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.83 Million | $-15.24 Million | -5.389x | -660.90% |
| 2024-12-31 | $-13.00 Million | $-12.49 Million | 0.961x | +146.84% |
| 2023-12-31 | $3.20 Million | $-6.56 Million | -2.051x | +32.34% |
| 2022-12-31 | $1.23 Million | $-3.73 Million | -3.032x | -314.66% |
| 2021-12-31 | $5.16 Million | $-3.77 Million | -0.731x | -87.58% |
| 2020-12-31 | $8.98 Million | $-3.50 Million | -0.390x | -114.12% |
| 2019-12-31 | $-1.41 Million | $-3.90 Million | 2.761x | +62.18% |
| 2018-12-31 | $-2.87 Million | $-4.89 Million | 1.703x | +378.73% |
| 2017-12-31 | $-16.57 Million | $-5.90 Million | 0.356x | -26.69% |
| 2016-12-31 | $-10.95 Million | $-5.31 Million | 0.485x | -25.92% |
| 2015-12-31 | $-6.97 Million | $-4.57 Million | 0.655x | -5.86% |
| 2014-12-31 | $-4.83 Million | $-3.36 Million | 0.696x | +139.18% |
| 2013-12-31 | $-11.06 Million | $-3.22 Million | 0.291x | -93.63% |
| 2012-12-31 | $-503.07K | $-2.30 Million | 4.566x | +330.72% |
| 2011-12-31 | $968.24K | $-1.92 Million | -1.979x | -- |
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications… Read more